<DOC>
	<DOCNO>NCT01142778</DOCNO>
	<brief_summary>This randomize , open-label study assess effect add Avastin ( bevacizumab ) Herceptin ( trastuzumab ) plus docetaxel neoadjuvant therapy patient early stage HER2-positive breast cancer . After 2 cycle Herceptin docetaxel every 3 week , patient response &lt; 70 % Positron Emission Tomography randomize 2:1 receive cycle 3 6 Herceptin ( 6mg/kg iv ) docetaxel ( 100mg/m2 iv ) without Avastin ( 15mg/kg iv ) . Patients response &gt; /=70 % receive Herceptin plus docetaxel cycle 3 6 . After surgery , patient receive 12 cycle Herceptin plus standard care treatment follow 5 year . Anticipated time study treatment 18 week .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Added Herceptin ( Trastuzumab ) Plus Docetaxel Neoadjuvant Setting Patients With Early Stage HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>female patient , &gt; /=18 year age early stage HER2positive breast cancer schedule receive neoadjuvant therapy objective conservative surgery ECOG performance status 0 , 1 2 partially totally lobular carcinoma inflammatory breast cancer bifocal and/or bilateral tumour metastasis previous treatment chemotherapy , radiation therapy hormone therapy breast cancer previous history cancer ( curatively treat basal squamous cell carcinoma skin and/or situ carcinoma cervix ) relapse within 5 year study entry situ contralateral breast carcinoma</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>